OPEN END TURBO LONG - ELI LILLY & CO | Real-time Bid/Ask 03:32:15 2024-07-12 EDT | ||
| 54.56 EUR / 54.63 EUR | -0.28% |
|
| Current month | +2.84% | ||
| 1 month | +5.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 54.46 | -0.53% |
| 24-07-11 | 54.75 | -1.14% |
| 24-07-10 | 55.38 | +0.73% |
| 24-07-09 | 54.98 | +3.33% |
| 24-07-08 | 53.21 | +3.08% |
Delayed Quote Börse Stuttgart
Last update July 12, 2024 at 02:29 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | Morgan Stanley |
| WKN | MB2QE7 |
| ISIN | DE000MB2QE77 |
| Date issued | 2023-01-24 |
| Strike | 340.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.34 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 55.53 € |
|---|---|
| Lowest since issue | 0.86 € |
| Spread | 0.06 € |
| Spread % | 0.11% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
934.1
USD
Average target price
887.2
USD
Spread / Average Target
-5.03%
- Stock Market
- Certificates
- Certificat
